
Monthly prescriptions for menopause hormone therapy in the United States jumped from about 2.0 million in 2023 to 4.9 million in 2026, signaling a major shift in how middle-aged women seek relief from symptoms.
Story Highlights
- Dispensing more than doubled to 4.9 million monthly prescriptions by 2026
- Use rose across patches, vaginal products, and progesterone; pills held steady
- Rates climbed from 28 to 67 prescriptions per 1,000 women aged 40–74
- The rise began in 2024 and continued through 2025–2026, spanning an FDA label change
What the Data Show About the Surge
Science News reported that pharmacy dispensing of menopause hormone therapy more than doubled in the United States. Monthly prescriptions rose from about 2.0 million in 2023 to 4.9 million in 2026, covering women aged 40 to 74. Researchers also estimated a jump in dispensing rates from 28 to 67 prescriptions per 1,000 women in that age group. The increase was broad. Use of estrogen patches, vaginal estrogen, and progesterone all climbed, while oral pills were roughly flat during the period.
The trend began in 2024 and kept building through 2025 and into 2026. That pattern spans a major move by the U.S. Food and Drug Administration (FDA). In late 2025, the FDA approved updated labeling for several menopause hormone therapy products to clarify risk information for heart disease, breast cancer, and blood clots. Because use was already rising before the change, the new labels may not fully explain the surge based on the available reporting.
Why This Reversal Matters After Two Decades of Decline
The rise looks like a rebound from the steep drop that followed the early 2000s Women’s Health Initiative headlines. After those reports, hormone therapy use fell sharply. National surveys later showed use down to less than 5% about a decade after 1999–2000, when it had been about 22% among women aged 40 and older. Recent reviews describe how doctors now tailor treatment to recently menopausal women with symptoms, rather than using hormones to prevent disease in older women.
Lower baseline use means a large percentage gain can still be a partial recovery. Public health groups have reminded clinicians and patients about known risks and benefits, which vary by age, timing, product, and dose. The FDA’s recent label updates aimed to clarify those trade-offs and reflect newer evidence reviews without removing important warnings altogether. That context helps explain how both caution and wider access can coexist as use rises.
Signals, Limits, and What Patients Should Ask
The pharmacy counts track prescriptions, not how many unique women used therapy or whether they took the medicine as directed. Refills, switches among products, and stockpiling can all raise the totals without one-to-one growth in new users. The Science News report did not list the study authors, the data vendor, or measures of uncertainty, which limits how precisely we can judge differences by age, location, or income from that single write-up. One brief caveat: these figures describe utilization, not outcomes.
Patients across the political spectrum often worry that regulators, drugmakers, and big clinics do not put their needs first. This story cuts both ways. On one hand, more women seem able to access symptom relief through patches and other forms. On the other, rising demand has already strained supplies of some estrogen patches, which the FDA linked to increasing demand, and that can push women to switch products or face delays. Clear guidance and steady supply chains are basic promises many feel the system still fails to keep.
What Comes Next for Care, Cost, and Trust
Doctors and patients are sorting through many moving parts at once: new labels, telehealth growth, targeted marketing, and ongoing debate over risks. Independent research could answer key questions the dispensing data cannot. Strong next steps include tracking unique users, new starts, and persistence over time, and testing whether the label changes shifted prescribing in a measurable way. Those answers would help women judge not only access, but also whether care is safer, more affordable, and more consistent over time.

















